<DOC>
	<DOCNO>NCT01671592</DOCNO>
	<brief_summary>This study evaluate safety feasibility MRI track vaccine produce person cancer cell inject intradermally day 3 consecutive day . One daily dose contain chemical detect MRI . That either 1st 3rd day 3 day course . On day MRI scan perform 6 24 hour injection day . Patients may able receive booster dos every 1-2 month</brief_summary>
	<brief_title>Safety Labeled Dendritic Cell ( DC ) Vaccines Feasibility Tracking Magnetic Resonance Imaging ( MRI )</brief_title>
	<detailed_description>STUDY EVALUATIONS - Pre-Vaccination - Complete physical examination ( ECOG performance status ( PS ) , medical history , weight , height , BSA ) ; exact size location tumor lesion note flow sheet , document text note , photographic and/or radiologic mean - CEA level blood ( tumor marker ) - Women childbearing potential serum beta-HCG pregnancy test - Anti-HIV , HbsAg Anti-HCV - CBC , platelet , differential - Comprehensive metabolic panel ( CMP ) include : glucose , BUN , creatinine , sodium , potassium , Cl , CO2 , calcium , total protein , albumin , alkaline phosphatase , AST , ALT , total bilirubin - PT/PTT test - Electrocardiogram ( EKG ) , indicate - Radiologic image evaluate status disease may perform part routine care . - Leukapheresis - Dendritic cell vaccine preparation - Procedures prim vaccination ( Days 1 3 ) - Complete physical examination ( PS weight ) - 19F/1H MRI scan day vaccination , 6 hr ( ±1 hour ) 24 hr ( ±4 hour ) post-injection . - Blood vitro assay , first i.d . administration day 1 ( baseline ) last i.d . administration day 3 - DTH test : administration day 1 readout day 3 - Biopsy DTH site perform subject consent biopsy , discretion investigator/sub-investigator ( Day 3 , base readout ) - Procedures Day 15 - Complete physical examination ( ECOG PS weight ) - CBC , platelet , differential - Blood vitro assay - Procedures booster course ( Days 36 38 , 64 66 , 91 93 ) - Complete physical examination ( PS weight ) 1st day 3 day course ( Days 36 , 64 , 91 ) - CBC , platelet , differential 1st day 3 day course ( Days 36 , 64 , 91 ) - Comprehensive metabolic panel ( CMP ) include : glucose , BUN , creatinine , sodium , potassium , Cl , CO2 , calcium , total protein , albumin , alkaline phosphatase , AST , ALT , total bilirubin 1st day 3 day course ( Days 36 , 64 , 91 ) - DTH test : administration 1st day readout 3rd day 2nd 3rd booster course ( Administration day 64 91 , readout day 66 93 ) - Biopsy DTH site perform subject consent biopsy , discretion investigator/sub-investigator ( 3rd day 3 day course , base readout DTH test ) - Blood vitro assay ( 1st 3rd day 3 day course ) - Procedures Day 105 - Complete physical examination ( ECOG PS weight ) - CEA level blood ( tumor marker ) - CBC , platelet , differential - Comprehensive metabolic panel ( CMP ) include : glucose , BUN , creatinine , sodium , potassium , Cl , CO2 , calcium , total protein , albumin , alkaline phosphatase , AST , ALT , total bilirubin - Radiologic image evaluate status disease may perform part routine care - Photography - Long term follow-up The subject lack disease progression 6 month last vaccination monitor disease free survival overall survival . Subjects may contact every 3 month within first three year study intervention , every six month year 5 , annually afterwards . In lieu direct contact medical record review may perform obtain data time point disease progression and/or survival .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects must adequate tumor tissue surgery , perform part conventional care . No chemotherapy , radiotherapy , major surgery , biologic therapy malignancy 2 week prior vaccine administration must recover side effect . An ECOG performance status 0 , 1 , 2 . Age equal 18 year old . Blood test : Platelet count great 80,000 ( platelet count , hematocrit , WBC reevaluate within 2 week prior leukapheresis ) Hematocrit &gt; 27.0 White blood count &gt; 2000/µL Creatinine less equal 2 X ULN Aware neoplastic nature his/her illness , experimental nature study intervention , alternative treatment , potential benefit risk , willing sign write informed consent document . Subjects currently treat systemic immunosuppressive agent , include steroid , ineligible 2 week removal immunosuppressive treatment . Subjects maintenance steroid adrenal insufficiency eligible . Subjects total bilirubin great 2 X ULN . Subjects uncontrolled pain . Subjects active autoimmune disease , positive serology HIV , HBV , HCV . ( Hypothyroidism allow . ) Subjects allergic develop allergy heparin . Subjects pregnant . Subjects sensitivity drug provide local anesthesia . Subjects medical contraindication MRI . Such contraindication include : Electrical implant cardiac pacemaker perfusion pump Ferromagnetic implant aneurysm clip , surgical clip , prosthesis , artificial heart , valve steel part , metal fragment , shrapnel , tattoo near eye steel implant Ferromagnetic object jewelry metal clip clothe Preexisting medical condition , include claustrophobic reaction , likelihood develop seizure great normal potential cardiac arrest</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>colorectal</keyword>
	<keyword>tumor</keyword>
	<keyword>neoplasm</keyword>
	<keyword>carcinoma</keyword>
	<keyword>vaccine</keyword>
</DOC>